Press Release

NASTAD Releases 2013 National AIDS Drug Assistance Program (ADAP) Monitoring Project Report

ADAP Continues to Grow and Meet Unprecedented Need in a Tough Economic Climate

January 16, 2013

Download the 2013 National AIDS Drug Assistance Program (ADAP) Monitoring Project Report (Module 1) (PDF)

Washington, D.C. -- Today, the National Alliance of State and Territorial AIDS Directors (NASTAD) released the first module of its 2013 National ADAP Monitoring Project Annual Report. The National ADAP Monitoring Project is NASTAD's long-standing effort to document new developments and challenges facing AIDS Drug Assistance Programs (ADAPs), assessing key trends over time, and providing the latest available data on the status of ADAPs. For the last 18 years, NASTAD has provided comprehensive analysis about ADAPs through the Report.

This year, NASTAD is releasing the report in two installments. Module One, being released today, includes detailed information related to ADAP budgets, client enrollment and utilization, client demographics, prescription distribution and payment methods, expenditures and prescriptions filled, insurance coordination, program eligibility, program management and administration, ADAP formulary coverage and hepatitis treatment coverage.

Module Two, which will be released in March 2013, will provide updated ADAP enrollment information and highlight ADAP's progress towards the implementation of health reform. These modules will be combined into a final, comprehensive report.

Highlights from Module One include:

  • In FY2011, ADAP expenditures on prescription drugs and insurance premiums, co-payments, and deductibles accounted for 95 percent of all program expenditures; only two percent of ADAP funding was expended on program administration.
  • For the first time in the history of ADAP, the budget has exceeded $2 billion, demonstrating the growing need of this safety net program in a challenging economic environment.
  • ADAP utilization reached its highest level, with the program serving almost 150,000 individuals in June 2012.
  • ADAPs reported an estimated $227 million in insurance expenditures for FY2012 as insurance has become a growing part of ADAP and has proven to be a cost-effective way to provide expanded access to medical care and medications.

ADAP continues to play a crucial role in ensuring and maintaining access to care for people living with HIV/AIDS (PLWHA), which is an important part of achieving the goals of the National HIV/AIDS Strategy and filling coverage gaps as implementation of the Affordable Care Act (ACA) moves forward. ADAP's role in providing medications to PLWHA is also essential for optimizing outcomes and preventing new infections, as illustrated in the prevention to care continuum.

"As Congress and the President work to solve the nation's fiscal crisis, it is important to emphasize that ADAP continues to be essential for filling widening coverage gaps for people living with HIV/AIDS," noted Julie Scofield, NASTAD's Executive Director. "Although fiscal year 2012 illustrated the resilience and flexibility of ADAP to continue growing and meeting unmet need, many states continue to experience increased strain on their programs and require additional funding to eliminate waiting lists and continue providing access to life-saving care and treatment for existing clients."

The federal government is currently being funded until March 2013 through a continuing resolution (CR) which essentially flat funds ADAP, the entire Ryan White Program, and other discretionary programs. This could result in a delay in FY2013 awards for ADAPs or the release of partial funding until final FY2013 funding is approved.

The current fiscal challenges facing the nation pose threats to access to life-saving medications for PLWHA through ADAP. Work must continue through a three-pronged approach that includes securing additional resources for ADAPs from the federal government; maintaining, restoring, and increasing resources for ADAPs from state governments; and, continuing pricing agreements between ADAPs and pharmaceutical manufacturers to provide financial stability and augmenting existing agreements, when applicable.

Learn more about ADAP here.

This article was provided by National Alliance of State and Territorial AIDS Directors. Visit NASTAD's website to find out more about their activities and publications.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.